Wedoany.com Report-Dec.8, Daehwa Pharmaceutical announced on Monday that its oral paclitaxel anticancer drug, Liporaxel Solution (paclitaxel DHP107 / RMX3001), has been successfully included in China's National Reimbursement Drug List (NRDL) by the National Healthcare Security Administration (NHSA). Reimbursement will take effect nationwide from 1 January 2026.

The NRDL listing allows Liporaxel Solution to be covered under the same insurance terms at all medical institutions across China, significantly lowering out-of-pocket costs for eligible patients.

Liporaxel is an innovative oral formulation that eliminates the need for intravenous administration, reducing hospitalization time, pre-treatment requirements and improving overall treatment convenience. The product received marketing authorisation from China's National Medical Products Administration (NMPA) for advanced gastric cancer in September 2024 and entered the market on a private-pay basis in January 2025.

Following negotiations with the NHSA, the reimbursed price has been established at 1,208 yuan (approximately US$171) per 300 mg/30 mL vial. Coverage applies to patients with advanced or metastatic gastric cancer whose disease has progressed during or after first-line fluorouracil (5-FU)-based therapy.

Daehwa Pharmaceutical will collaborate closely with its local partners, Haihe Biopharma and 3SBio, to expand distribution channels, secure prescriptions in major hospitals and ensure stable supply. The company also plans to pursue additional indications, including breast cancer, to broaden clinical use.

A Daehwa Pharmaceutical official said: "The NRDL listing of Liporaxel Solution is a major milestone, recognizing Daehwa's technology and therapeutic innovation in China. By working closely with our partners, we will strengthen our execution in the local market and aim to raise Daehwa's profile in the global anticancer drug market."

The inclusion is expected to accelerate prescription growth and reinforce Daehwa’s position in China’s oncology sector.